Sweet success? SGLT2 inhibitors and diabetes

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

nents, can lead to de novo ESRD in subjects without identifiable ESRD risks. These data also increase the urgency to identify kidney toxic dietary components and if these components can promote ESRD even in subjects who have no identifiable risk factors. Diet remains a relatively underused component of the clinician’s armamentarium in the fight to prevent patients with CKD progressing to ESRD a...

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential b...

SGLT2 Inhibitors and the Diabetic Kidney.

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...

Mechanism of Action of Sglt2-inhibitors

T2DM individuals manifest a 2-3 times greater risk of CV events compared to non-diabetics, and CV mortality is responsible for ~70% of total mortality. In T2DM patients without MI, risk of CV death is similar to individuals without diabetes with prior MI.1 Although hyperglycemia is a strong risk factor for microvascular complications, it is a weak risk factor for CV disease (CVD), and intervent...

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes